BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 6091520)

  • 1. [Pharmacologic value of cyclic nucleotide phosphodiesterase inhibitors].
    Nemoz G; Prigent AF
    Ann Pharm Fr; 1984; 42(2):99-112. PubMed ID: 6091520
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacological inhibition of calmodulin-sensitive phosphodiesterases.
    Ilien B; Ruckstuhl M; Landry Y
    J Pharmacol; 1982; 13(2):307-16. PubMed ID: 6285085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective inhibitor of platelet cyclic adenosine monophosphate phosphodiesterase, cilostamide, inhibits platelet aggregation.
    Hidaka H; Hayashi H; Kohri H; Kimura Y; Hosokawa T; Igawa T; Saitoh Y
    J Pharmacol Exp Ther; 1979 Oct; 211(1):26-30. PubMed ID: 226672
    [No Abstract]   [Full Text] [Related]  

  • 4. Analysis of the relationship between pharmacological inhibition of cyclic nucleotide phosphodiesterase and relaxation of canine tracheal smooth muscle.
    Polson JB; Krzanowski JJ; Anderson WH; Fitzpatrick DF; Hwang DP; Szentivanyi A
    Biochem Pharmacol; 1979 Apr; 28(8):1391-5. PubMed ID: 87201
    [No Abstract]   [Full Text] [Related]  

  • 5. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents.
    Marcoz P; Prigent AF; Lagarde M; Nemoz G
    Mol Pharmacol; 1993 Nov; 44(5):1027-35. PubMed ID: 8246905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of human lung cyclic GMP and cyclic AMP phosphodiesterases by certain nucleosides, nucleotides, and pharmacological phosphodiesterase inhibitors.
    Glass WF; Moore JB
    Biochem Pharmacol; 1979 Apr; 28(7):1107-12. PubMed ID: 87197
    [No Abstract]   [Full Text] [Related]  

  • 7. Inhibitors of cyclic nucleotide phosphodiesterase isoenzymes--their potential utility in the therapy of asthma.
    Nicholson CD; Shahid M
    Pulm Pharmacol; 1994 Feb; 7(1):1-17. PubMed ID: 8003849
    [No Abstract]   [Full Text] [Related]  

  • 8. Hypertrophied right hearts get two for the price of one: can inhibiting phosphodiesterase type 5 also inhibit phosphodiesterase type 3?
    Kass DA
    Circulation; 2007 Jul; 116(3):233-5. PubMed ID: 17638937
    [No Abstract]   [Full Text] [Related]  

  • 9. Inhibitors of cyclic nucleotide phosphodiesterases as therapeutic agents.
    Murray KJ; England PJ
    Biochem Soc Trans; 1992 May; 20(2):460-4. PubMed ID: 1327922
    [No Abstract]   [Full Text] [Related]  

  • 10. Phosphodiesterase inhibitors as tools in cyclic nucleotide research: a precautionary comment.
    Wells JN; Kramer GL
    Mol Cell Endocrinol; 1981 Jul; 23(1):1-9. PubMed ID: 6167475
    [No Abstract]   [Full Text] [Related]  

  • 11. Dihydro- and tetrahydroisoquinolines as inhibitors of cyclic nucleotide phosphodiesterases from dog heart. Structure-activity relationships.
    Van Inwegen RG; Salaman P; St Georgiev V; Weinryb I
    Biochem Pharmacol; 1979 Apr; 28(8):1307-12. PubMed ID: 87199
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of cyclic AMP- and cyclic GMP- phosphodiesterase inhibitors on immunological release of histamine and on lung contraction.
    Frossard N; Landry Y; Pauli G; Ruckstuhl M
    Br J Pharmacol; 1981 Aug; 73(4):933-8. PubMed ID: 6168323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do conventional plasma cyclic nucleotide phosphodiesterase inhibitors really work in all situations?
    Wood PJ; Pao G; Ross G; Smith C
    Clin Chim Acta; 1981 Sep; 115(3):405-8. PubMed ID: 6271425
    [No Abstract]   [Full Text] [Related]  

  • 14. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
    Ko WC; Shih CM; Lai YH; Chen JH; Huang HL
    Biochem Pharmacol; 2004 Nov; 68(10):2087-94. PubMed ID: 15476679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1-(4-Aminobenzyl)-and 1-(4-aminophenyl)isoquinoline derivatives: synthesis and evaluation as potential irreversible cyclic nucleotide phosphodiesterase inhibitors.
    Walker KA; Boots MR; Stubbins JF; Rogers ME; Davis CW
    J Med Chem; 1983 Feb; 26(2):174-81. PubMed ID: 6298424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective inhibition of separated forms of cyclic nucleotide phosphodiesterase from rat heart by some cardio- or vaso-active butenolide derivatives.
    Némoz G; Prigent AF; Picq M; Pacheco H
    Biochem Pharmacol; 1982 Nov; 31(21):3353-8. PubMed ID: 6293510
    [No Abstract]   [Full Text] [Related]  

  • 17. Methylxanthine inhibitors of phosphodiesterases.
    Wells JN; Miller JR
    Methods Enzymol; 1988; 159():489-96. PubMed ID: 2457788
    [No Abstract]   [Full Text] [Related]  

  • 18. [Pharmacodynamic aspects of theophylline].
    Marmo E
    Clin Ter; 1983 Jul; 106(2):87-94. PubMed ID: 6313282
    [No Abstract]   [Full Text] [Related]  

  • 19. Selective inhibition of cyclic AMP and cyclic GMP phosphodiesterases of cardiac nuclear fraction.
    Ahluwalia GS; Rhoads AR
    Biochem Pharmacol; 1982 Mar; 31(5):665-9. PubMed ID: 6177320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isoenzyme-selective cyclic nucleotide phosphodiesterase inhibitors: effects on airways smooth muscle.
    Raeburn D; Advenier C
    Int J Biochem Cell Biol; 1995 Jan; 27(1):29-37. PubMed ID: 7757880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.